Evidence map›Paper›PMID 28806263›Full record

Trial reportClinical nuclear medicine2017

18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology.

Baris Turkbey, Esther Mena, Liza Lindenberg, Stephen Adler, Sandra Bednarova, Rose Berman, Anita T Ton, Yolanda McKinney, Philip Eclarinal, Craig Hill and 9 more

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical nuclear medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02190279 (A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02190279 early_phase1completednot on this map

A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2014 to 2018Enrolled116ConditionsProstatic Neoplasms, Prostate CancerArms18F DCFBC, Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Radiology. Imaging cancer · 2022
    Pooled it
  3. Trial
  4. Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Novel PET imaging methods for prostate cancer.World journal of urology · 2021
    Review
  11. Prospective Evaluation ofAJR. American journal of roentgenology · 2020
    Article
  12. Theranostics · 2020
    Review
  13. Improved specificity withEuropean journal of nuclear medicine and molecular imaging · 2019
    Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Baris TurkbeyFrom the *Molecular Imaging Program, National Cancer Institute, Bethesda; †Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc, Frederick, MD; ‡Institute of Diagnostic Radiology, Department of Medical Area, University of Udine, Udine, Italy; §Office of the Clinical Director/Center for Cancer Research/National Cancer Institute, Bethesda; ∥Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick; ¶Office of the Pharmaceutical Quality, FDA/CDER, Silver Spring; **Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore; ††Laboratory of Pathology, National Cancer Institute, Bethesda; ‡‡Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville; §§Center for Interventional Oncology, National Cancer Institute and Clinical Center, and Radiology Imaging Sciences, National Institutes of Health, Bethesda; and ∥∥Urologic Oncology Branch, National Cancer Institute, Bethesda, MD.
Esther Mena
Liza Lindenberg
Stephen Adler
Sandra Bednarova
Rose Berman
Anita T Ton
Yolanda McKinney
Philip Eclarinal
Craig Hill
George Afari
Sibaprasad Bhattacharyya
Ronnie C Mease
Maria J Merino
Paula M Jacobs
Bradford J Wood
Peter A Pinto
Martin G Pomper
Peter L Choyke

Funding

Center for Interventional OncologyZIDBC011242 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WOOD, BRADFORD J · 2009 to 2025
$18.7M
Interventional OncologyZIACL040015 · CLC · CLINICAL CENTER · PI WOOD, BRADFORD · 2009 to 2025
$0k
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z99 CA999999NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

purposeTo assess the ability of (N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-F-fluorobenzyl-L-cysteine) (F-DCFBC), a prostate-specific membrane antigen-targeted PET agent, to detect localized prostate cancer lesions in correlation with multiparametric MRI (mpMRI) and histopathology.

methodsThis Health Insurance Portability and Accountability Act of 1996-compliant, prospective, institutional review board-approved study included 13 evaluable patients with localized prostate cancer (median age, 62.8 years [range, 51-74 years]; median prostate-specific antigen, 37.5 ng/dL [range, 3.26-216 ng/dL]). Patients underwent mpMRI and F-DCFBC PET/CT within a 3 months' window. Lesions seen on mpMRI were biopsied under transrectal ultrasound/MRI fusion-guided biopsy, or a radical prostatectomy was performed. F-DCFBC PET/CT and mpMRI were evaluated blinded and separately for tumor detection on a lesion basis. For PET image analysis, MRI and F-DCFBC PET images were fused by using software registration; imaging findings were correlated with histology, and uptake of F-DCFBC in tumors was compared with uptake in benign prostatic hyperplasia nodules and normal peripheral zone tissue using the 80% threshold SUVmax.

resultsA total of 25 tumor foci (mean size, 1.8 cm; median size, 1.5 cm; range, 0.6-4.7 cm) were histopathologically identified in 13 patients. Sensitivity rates of F-DCFBC PET/CT and mpMRI were 36% and 96%, respectively, for all tumors. For index lesions, the largest tumor with highest Gleason score, sensitivity rates of F-DCFBC PET/CT and mpMRI were 61.5% and 92%, respectively. The average SUVmax for primary prostate cancer was higher (5.8 ± 4.4) than that of benign prostatic hyperplasia nodules (2.1 ± 0.3) or that of normal prostate tissue (2.1 ± 0.4) at 1 hour postinjection (P = 0.0033).

conclusionsThe majority of index prostate cancers are detected with F-DCFBC PET/CT, and this may be a prognostic indicator based on uptake and staging. However, for detecting prostate cancer with high sensitivity, it is important to combine prostate-specific membrane antigen PET/CT with mpMRI.

Indexed as

Magnetic Resonance ImagingPositron Emission Tomography Computed TomographyAgedAntigens, SurfaceCysteineGlutamate Carboxypeptidase IIHumansMaleMiddle AgedProspective StudiesProstatectomyProstatic NeoplasmsAntigens, SurfaceCysteineFOLH1 protein, humanGlutamate Carboxypeptidase IIN-(N-((S)-1,3-Dicarboxypropyl)carbamoyl)-4-(18F)fluorobenzyl-L-cysteine

Identifiers

PMID28806263
PMCPMC5703072

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.